Metacrine Raises $36M in Series A

What does Metacrine do?

Metacrine, is a privately held biotechnology company which is focused on targeting metabolic disease through advances in endocrine research. The company licensed from Howard Hughes Medical Institute Investigator at the Salk Institute and from the laboratory of Dr.Ronald Evans, a world leader in nuclear home receptors. This biotech company leverages 2 mechanically distinct programs for targeting steatohepatitis, diabetes and other liver and metabolic disorders. The company will leverage the novel discoveries and exclusive licensed IP of the Evans Lab for developing 2 classes of novel therapeutics.

How much Metacrine was funded?

Metacrine raised $36M in Series A funding on August 5, 2015 from ARCH Venture Partners, Polaris Partners, EcoR1 Capital and venBio.

What is next for Metacrine?

The San Diego biotech company has raised $36 M for advancing its 2 new classes of drugs which could be used for helping controlling chronic liver disease and related metabolic disorders and diseases. Apart from the funding, it has appointed Neil McDonnell as Chief Executive Officer and the formation of a senior leadership team and board of directors led by Executive Chairman Richard Heyman.

The company is advancing technology licensed from the Evans Lab, Howard Hughes Medical Institute Investigator and director of the Gene Expression Laboratory at the Salk Institute. Metacrine will leverage the exclusively licensed intellectual property and discoveries of the Evans lab for developing 2 classes of novel therapeutics, to target non-alcoholic steatohepatitis, diabetes and other metabolic diseases and liver disorders.

More about Metacrine

Metacrine was founded in 2015 by Richard Heyman, Ronald Evans, and Michael Downes. It has its headquarters in Carmel Vally, San Diego, California. Currently it has 14 employees and has plans to add more. The company is focused on advancing research in nuclear hormone receptors for treating metabolic diseases. Metacrine’s technology is based on Evan’s research and is licensed from the Salk Institute.